Vera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INC

Explicit Guidance:

• Regulatory Milestones: Supplemental BLA for Atacicept (Trutacna) will be submitted this quarter (Q4 2023); FDA review anticipated to result in full approval and updated label in mid-2027.
• Commercial Updates: Third-quarter earnings call and commercial update scheduled for November 2023.
• Clinical Data Submission: Additional data on Atacicept in adolescents and Membranous Nephropathy to be presented at ASN and NEJM publication; further dosing frequency study data expected this quarter.

Business-Segment Outlook:

• Product Lifecycle: Atacicept (Trutacna) is currently in commercial launch in the US following accelerated approval; sales force detailing is currently restricted to the existing label but expected to "unlocked" with full approval in mid-2027.
• Pipeline Expansion: Active clinical programs include:
  • Adolescents: Additional efficacy data for Atacicept in IgA nephropathy adolescents released.
  • Adjacent Indication: First data presented for Atacicept in Membranous Nephropathy (autoantibody-driven kidney disease).
• Labeling Strategy: Full approval label aims to include composite endpoints (avoidance of dialysis, transplant, death) and GFR annual slope difference, moving beyond current surrogate proteinuria endpoints to drive uptake.

Market and Competitive Outlook:

• Standard of Care Shift: Anticipated transition from steroid-based treatment to precise immune modulation (Atacicept), with steroids expected to move into "history books" for IgA nephropathy within the next few years due to toxicity and limited long-term efficacy of steroids.
• Therapeutic Paradigm: Validation of dual BAF and APRIL inhibition via two independent trials (Vera and competitor) confirming efficacy and safety, establishing this mechanism as a robust standard rather than an anomaly.
• Treatment Initiation: Medical community moving toward "no wait" strategy, initiating simultaneous disease-modifying (Atacicept) and CKD-supportive therapy (RAS inhibitors/SGLT2s) immediately upon diagnosis of risk (proteinuria >0.5g/day), eliminating "watchful waiting" periods.
• Diagnosis Inflection: Expect significant increase in IgA nephropathy diagnoses (potentially doubling current estimates) driven by earlier identification of genetic risk and increased biopsy rates as awareness of the transformative treatment landscape grows.

Macro / Industry Outlook:

• Clinical Trial Design: FDA and industry shifting toward 52-week GFR endpoints as primary approval drivers for transformative therapies, replacing traditional 2-year designs to protect patient safety and maintain trial integrity; Vera's approach is expected to set the precedent for future IgA nephropathy trials.
• Regulatory Precedent: Successful adaptation of endpoints (shortening to 52 weeks) validates a new regulatory pathway for drugs demonstrating profound disease modification and safety profiles.
• Long-term Therapy Expectations: Industry anticipating 30–40 years of treatment for chronic disease management, necessitating long-term safety monitoring beyond current trial durations.

Strategic Initiatives:

• Dosing Optimization: Running dose-range/frequency study evaluating monthly dosing options (data to be released later this quarter) to potentially reduce administration frequency compared to current weekly schedule.
• Trial Expansion: All patients in the ORIGIN-3 trial transitioning to open-label Atacicept for continued follow-up through week 156 to assess long-term efficacy and safety.
• Market Education: Active engagement with nephrologists, general practitioners, and urologists to promote earlier diagnosis, referral, and biopsy adoption to capture patients before significant kidney function loss occurs.

Risks and Headwinds to Outlook:

• Adoption Barriers: Potential delay in full commercial uptake until mid-2027 due to reliance on full FDA approval and updated label; sales team currently restricted from detailing the expanded composite endpoint data.
• Clinical Practice Transition: Challenge of shifting nephrologists away from entrenched RAS inhibitor monotherapy and steroid use; requires cultural and educational shifts in clinical practice.
• Data Interpretation: Residual proteinuria may persist despite GFR stabilization, potentially causing confusion regarding treatment efficacy until long-term clinical data clarifies the dissociation between proteinuria levels and GFR protection.
• Long-term Safety Unknowns: While 2-year data is reassuring, lifelong exposure risks (e.g., infection, immunoglobulin levels) require continued monitoring and longer-term data collection.

Management Tone on the Future:

• Confidence Level: High confidence and enthusiasm regarding the "paradigm shift" and "frame shift" in treating IgA nephropathy; management views the data as "transformative" capable of preventing end-stage renal disease (dialysis/transplant).
• Strategic Positioning: Positioning Atacicept as the first therapy to return kidney function loss rates to "physiological norms" (healthy individuals), distinguishing it from hemodynamically acting drugs with lesser efficacy.
• Patient-Centricity: Strong emphasis on patient safety and trial ethics, citing the decision to unblind the trial early to protect placebo-group patients from disease progression as a key strategic differentiator.

Miscellaneous:

• Safety Profile: No deaths, dialysis, or transplants in the treatment arm; no clinically relevant anti-drug antibodies impacting efficacy or safety; safety profile comparable to placebo with lower serious adverse event rates in the Atacicept group.
• Patient Population: ORIGIN-3 enrolled the "highest risk" population to date (average age 40, significant residual proteinuria despite standard of care), validating efficacy in severe disease states.
• Competitor Context: Acknowledged separate trial (Votizem/Voiset/Abiogen) showing similar dual-inhibition efficacy; management advises against direct "apples-to-apples" comparisons due to differences in patient risk profiles and trial duration, noting Vera's data reflects a sicker population with shorter follow-up but high statistical significance.